louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04651179: Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma
Official title: A Retrospective Observational Study of the Effectiveness of Gemcitabine -Docetaxel in Patients With Relapsed Osteosarcoma Who Have Been Treated With HD-IFO in First Line Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Osteosarcoma Recurrent
Osteosarcoma Metastatic
Lead sponsor: Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Sponsor class: OTHER
First posted: 2020-12-03
Enrollment: 33
Sex: ALL
Minimum age (years): 4
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with relapsed osteosarcoma treated with gemcitabine- docetaxel after a first line with HD- IFO

Brief summary: A retrospective observational study of the effectiveness of gemcitabine - docetaxel in patients with relapsed osteosarcoma who have been treated with HD IFO in first line treatment


Eligibility criteria: Inclusion Criteria:

* Age at diagnosis of high grade osteosarcoma \>= 4
* Received first line treatment with HD IFO
* Following HD IFO treatment, they have been diagnosed refractory disease and they satisfy at least one of the following criteria :

  1. Relapsed in the first 24 month following the initial diagnosis, regardless of location and resectability
  2. Lung relapsed disease with more than 2 nodules diagnosed over 24 months from the initial diagnosis
  3. Non resectable relapsed disease diagnosed over 24 months from the initial diagnosis Before or during GEMDOX treatment, eligible patients may have been subject to metastasectomy

Exclusion Criteria: none

Primary outcomes:
measure: Response to Gemcitabina - Docetaxel Treatment
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: Istituto Nazionale Tumori
state: Milano
city: Candiolo
country: Italy
facility: Fondazione del Piemonte per l' Oncologia IRCCS Candiolo
state: Turin
city: Bologna
country: Italy
facility: Istituto Ortopedico Rizzoli
city: Florence
country: Italy
facility: AOUC Azienda Ospedaliero-Universitaria Careggi
city: Milan
country: Italy
facility: IRCCS Istituto Nazionale dei Tumori
city: Pisa
country: Italy
facility: Azienda Ospedaliero Universitaria pisana
city: Rome
country: Italy
facility: IRCCS Istituti Fisioterapici Ospitalieri
city: Turin
country: Italy
facility: AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita
Study officials:
affiliation: AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita
name: Franca Fagioli, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06837779: Exposed Hypersensitive Dentin Treated With Fluoride Iontophoresis With Remineralizing Agents
Official title: Clinical Evaluation of Exposed Hypersensitive Dentin Treated With Fluoride Iontophoresis Application in Comparison With Two Different Remineralizing Agents (a Randomized Clinical Trial)
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Dentin Hypersensitivity
Keywords: hypersinsitivity
flouride iontophoresis
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2025-02-20
Enrollment: 20
Sex: ALL
Minimum age (years): 35
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn if the application of fluoride works to treat patients suffering from dentin hypersensitivity. It will also learn about the safety of using fluoride iontophoresis with Acidulated phosphate fluoride gel.

The main questions it aims to answer are:

Does the remineralizing agent have the ability to decrease dentin sensitivity?

Researchers will compare Fluoride Iontophoresis with Acidulated Phosphate Fluoride gel , Casein phosphopeptides-Amorphus calcium phosphate (CPP-ACP), nano-hydroxyapptite (NHAP) and -active glass in decreasing dentin hypersensitivity

.

Participants will:

* Application of remineralizing agent every 3 months
* Visit the dental clinic once every 3 months for checkups and tests

Detailed description: Assess the efficacy of fluoride iontophoresis in remineralization in comparison with other ingredients.

Eligibility criteria: Inclusion Criteria:

* Patients within 35-60 years of age.
* Each patient has 4 or more exposed roots of posterior teeth having sensitivity.
* Good oral hygiene.
* Patients who will agree to the consent and will commit to the follow-up period.
* Patients will follow instructions during study time.
* Teeth that were vital.

Exclusion Criteria:

* Patients with any systemic disease that may affect normal healing.
* Patient with bad oral hygiene, high caries index and high plaque index
* Patients participating in more than 1 dental study.
* Active carious lesions.
* Intrinsic and extrinsic stains.
* Any previous filling of selected teeth.
* Cracked and malformed teeth.

Primary outcomes:
measure: Visual Analogue Scale
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dental Medicine ,Alazhar Univerisity
Study officials:
affiliation: Alazhar Univeristy
name: Mohamed Wakwak, A
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02728479: Percutaneous Transluminal Angioplasty Registry
Official title: PTA Registry - an Observational Study of Percutaneous Transluminal Angioplasty
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Percutaneous Transluminal Angioplasty
Lead sponsor: Heinrich-Heine University, Duesseldorf
Sponsor class: OTHER
First posted: 2016-04-05
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing PTA

Brief summary: Percutaneous transluminal angioplasty (PTA) is a minimally invasive procedure for dilating blood vessels in the treatment of peripheral artery disease.

The aim of this registry is to collect prospectively and systematically clinical research data from patients undergoing PTA. This registry is an open-end observational study to assess the characteristics and outcomes in patients with undergoing PTA.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing PTA

Exclusion Criteria:

* \< 18 years

Primary outcomes:
measure: Patency rate
timeFrame: 6 months
measure: Creatinine level
timeFrame: 2 Days after PTA
Secondary outcomes:
measure: Mortality
timeFrame: 30 days
measure: Days of Hospitalization
timeFrame: 12 months
measure: Ankle-Brachial Index
timeFrame: 6 months and 12 months
measure: walking distance
timeFrame: 6 months and 12 months
measure: Restenosis rate
timeFrame: 12 months
Other outcomes:
Locations:
city: Düsseldorf
country: Germany
facility: Division of Cardiology, Pulmonary Disease and Vascular Medicine
Study officials:
affiliation: Division of Cardiology, Pulmonary Disease and Vascular Medicine
name: Christian Heiss, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Busch L, Heinen Y, Stern M, Wolff G, Ozaslan G, Tzetou K, Sansone R, Heiss C, Kelm M. Angioplasty of Flow-Limiting Stenosis Reduces Aortic and Brachial Blood Pressure in Patients With Peripheral Artery Disease. J Am Heart Assoc. 2021 Jul 20;10(14):e019724. doi: 10.1161/JAHA.120.019724. Epub 2021 Jul 6.
Clinical trial NCT00370279: Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Pseudophakic Retinal Detachment
Aphakic Retinal Detachment
Keywords: Pseudophakic retinal detachment,
Aphakic retinal detachment,
Scleral buckling,
Primary vitrectomy,
Proliferative vitreoretinopathy
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2006-08-31
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the visual and anatomical outcomes and complications of four surgical techniques (1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy) for management of pseudophakic and aphakic retinal detachment


Eligibility criteria: Inclusion Criteria:

* Cases of pseudophakic and aphakic retinal detachment with PVR grade A or B

Exclusion Criteria:

* PVR grade C
* History of surgery for RD
* Signs of diabetic retinopathy, AMD, glaucoma and macular hole
* History of ocular trauma
* Giant retinal tear

Primary outcomes:
measure: Retinal reattachment rate
measure: Visual acuity
Secondary outcomes:
measure: Proliferative vitreoretinopathy
measure: Macular Pucker
measure: Anisometropia
measure: Choroidal detachment
measure: Reoperation
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Hamid Ahmadieh, MD
Study officials:
affiliation: Ophthalmic Research Center of Shaheed Beheshti Medical University
name: Hamid Ahmadieh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04622579: Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years
Official title: Lenalidomide Combined With Rituximab as Front-line Therapy in Elderly Patients Aged Over 80 Years With Diffuse Large B Cell Lymphoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Diffuse Large B Cell Lymphoma
Age Over 80 Years
Keywords: lenalidomide
Lead sponsor: Guangdong Provincial People's Hospital
Sponsor class: OTHER
Collaborators: name: Guangzhou First People's Hospital
name: First People's Hospital of Foshan
name: Huizhou Municipal Central Hospital
name: Shantou Central Hospital
First posted: 2020-11-10
Enrollment: 20
Sex: ALL
Minimum age (years): 80
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: About 40% of Diffuse large B cell lymphoma relapse or is refractory, age is a prognostic factor of DLBCL, as elderly patients are not capable to received standard treatment, the prognosis of elderly patients is poor especially those aged over 80 years. In this study,we aimed to investigate the safety and efficacy of the combination of lenalidomide and rituximab in elderly patients aged ≥ 80 years with untreated DLBCL.


Eligibility criteria: Inclusion Criteria:

1. Age≧80 years ;
2. ECOG score 0-2；
3. untreated with pathologically conﬁrmed CD20+ DLBCL ;
4. expected life expectancy of ≥ 12 weeks;
5. capable of swallowing tablets;
6. GFR(by Cockcroft- Gault)≥30 ml/min;
7. can sign written informed consent to participate in the study.

Exclusion Criteria:

1. with CNS involvement;
2. with other malignancy (not including adequate-treated non-melanoma cutaneum carcinoma); patients with other cancer but disease-free for ≥5 years can enter this study;
3. with ≥ grade 2 peripheral neurophathy;
4. with cardiopathy including unstable angia or myocardial infarction over the past 8 weeks;
5. received live vaccine within 28 days.;
6. HIV-positive;
7. thrombosis ;
8. GFR\<30 mL/min;
9. other conditions not suitable for rituximab or lenalidomide application.

Primary outcomes:
measure: ORR
timeFrame: 24 months
Secondary outcomes:
measure: CR
timeFrame: 24 months
measure: OS
timeFrame: from date of treatment until the date of death from any cause, assessed up to 5 years
measure: PFS
timeFrame: from date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangdong provincial people's hospital
state: Guangdong
Study officials:
References:
Clinical trial NCT00027079: Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Alcoholism
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Sponsor class: NIH
First posted: 2001-11-21
Enrollment: 360
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: This study will compare the effectiveness of ondansetron (Zofran) and naltrexone (ReVia) both alone and in combination in treating Early Onset Alcoholics versus Late Onset Alcoholics. All subjects will received standardized Cognitive Behavioral Therapy. Followup assessments will be completed at 1, 3, 6, and 9 months after treatment.


Eligibility criteria: Inclusion Criteria:

* Current diagnosis of alcohol dependence.
* Provide a written informed consent.
* Must weigh within 30% of their ideal body weight.
* Patients must weigh at least 89 lbs. and no more than 342 lbs.
* Good physical health.
* Currently drinking 14 or more alcohol units per week for women and 21 or more alcohol units per week for men in the last 30 days.
* Provide evidence of stable residence in the last month prior to enrollment in the study.
* No plans to move in the nine months after entering the study.
* Literate in English and able to read, understand, and complete questionnaires and follow instructions.
* Willingness to participate in behavioral treatment for alcoholism.

Exclusion Criteria:

* Current psychiatric disorder other than alcohol or nicotine dependence.
* Elevated liver enzymes or elevated bilirubin.
* Severe alcohol withdrawal symptoms which require treatment.
* Serious medical co-morbidity requiring medical intervention or close supervision.
* Severe or life-threatening adverse reactions to medications in the past or during this trial.
* Female patients who are pregnant, lactating, or not adhering to an acceptable form of contraception at any time during the study.
* Received inpatient or outpatient treatment for alcohol dependence within the last 30 days.
* Compelled to participate in an alcohol treatment program for alcohol dependence to maintain their liberty.
* Members of the same household.
* Tuberculosis.
* Current treatment with any medications having a potential effect on alcohol consumption and related behaviors or mood.
* Urine must be free of opiates, cocaine, amphetamines, barbiturates, benzodiazepines, prescription and non-prescription drugs.
* Pyrexia of unknown origin.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: University of Texas Health Science Center
state: Texas
Study officials:
References:
Clinical trial NCT05923879: Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
Official title: Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Lymphoma, Large B-Cell, Diffuse
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2023-06-28
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Over 18-year-old recurrent or refractory diffuse large B-cell lymphoma patients receiving Selinexor combined with lenalidomide and rituximab would be enrolled.

Brief summary: This is a retrospective observational study of the therapeutic mechanism and resistance mechanism of the treatment of Selinexor combined with lenalidomide and rituximab in diffuse large B-cell lymphoma patients. By detecting the immune cells in peripheral blood and tumor tissues of patients before and after treatment, the key immune cell subsets and immune molecules linked to the action and resistance of the treatment of Selinexor combined with lenalidomide and rituximab, so as to provide the basis for the optimization of the treatment or the combination of other immunotherapies.


Eligibility criteria: Inclusion Criteria:

1. At least 18 years old.
2. Histopathologically confirmed diffuse large B-cell lymphoma according to World Health Organization (WHO) classification criteria 2016.
3. There is evidence of relapsed or refractory disease.
4. Treatment with Selinexor combined with lenalidomide and rituximab.

Exclusion Criteria:

* No

Primary outcomes:
measure: Tumor tissues collected before treatment and at the point of progression if available for DNA sequencing after quality control.
timeFrame: 2023/06/30-2025/06/30
measure: Tumor tissues collected before treatment and at the point of progression if available for RNA sequencing after quality control.
timeFrame: 2023/06/30-2025/06/30
measure: Peripheral blood collected before each cycle and at the point of progression if available for Mass Cytometry.
timeFrame: 2023/06/30-2025/06/30
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Study officials:
References:
Clinical trial NCT05864079: Developmental Endothelial Locus-1, Platelet Count, and Soluble P-selectin in Overweight and Obese Subjects
Official title: Serum Levels of Developmental Endothelial Locus-1 and Its Relationship With Platelet Count and Soluble P-selectin in Overweight and Obese Subjects
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Overweight and Obesity
Lead sponsor: Aswan University Hospital
Sponsor class: OTHER
First posted: 2023-05-18
Enrollment: 66
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy overweight and obese subjects

Brief summary: This observational study aims to detect serum levels of Developmental Endothelial Locus-1 (DEL-1), Platelet Count, and Soluble P-selectin (sP-sel) in Overweight and Obese Subjects. The main questions it aims to answer are:

* Is there a difference in serum DEl-1 levels in overweight and obese subjects compared to normal subjects?
* Are there any relations between serum DEL-1 levels, sP-sel, and platelet count in overweight and obese subjects ?


Eligibility criteria: Inclusion Criteria:

* Male patients.
* Age (18-65) years.
* Healthy overweight and subjects.

Exclusion Criteria:

* Patients with cardiovascular diseases.
* Diabetic patients.
* Previous history of thrombo-embolic diseases.
* Patients with hyperthyroidism.
* Patients with any type of malignancy.
* Underlying hepatic or renal failure.
* Major surgery within 60 days.

Primary outcomes:
measure: Platelet count
timeFrame: 6 months
measure: Serum Developmental endothelial locus-1 levels
timeFrame: 6 months
measure: Serum Soluble P-selectin levels
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Aswan
country: Egypt
facility: Aswan University Hospital
Study officials:
affiliation: Aswan University Hospital
name: Asmaa Abdelmageed Muhammed, lecturer
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hajishengallis G, Chavakis T. DEL-1-Regulated Immune Plasticity and Inflammatory Disorders. Trends Mol Med. 2019 May;25(5):444-459. doi: 10.1016/j.molmed.2019.02.010. Epub 2019 Mar 15.
citation: Purdy JC, Shatzel JJ. The hematologic consequences of obesity. Eur J Haematol. 2021 Mar;106(3):306-319. doi: 10.1111/ejh.13560. Epub 2020 Dec 13.
citation: Barale C, Russo I. Influence of Cardiometabolic Risk Factors on Platelet Function. Int J Mol Sci. 2020 Jan 17;21(2):623. doi: 10.3390/ijms21020623.
citation: Kwon CH, Sun JL, Kim MJ, Abd El-Aty AM, Jeong JH, Jung TW. Clinically confirmed DEL-1 as a myokine attenuates lipid-induced inflammation and insulin resistance in 3T3-L1 adipocytes via AMPK/HO-1- pathway. Adipocyte. 2020 Dec;9(1):576-586. doi: 10.1080/21623945.2020.1823140.
Clinical trial NCT03361579: Pain Response to Open Label Placebo in Induced Acute Pain in Healthy Male Adults
Official title: Pain Response to Open Label Placebo in Induced Acute Pain in Healthy Male Adults - A Randomized Single Blinded Clinical Trail
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Pain
Keywords: Placebo
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2017-12-05
Enrollment: 35
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: investigator blinded, cross over design
Primary purpose: TREATMENT

Brief summary: Open Label Placebo application has been shown to be effective in treatment of chronic pain (low back pain) and disease like the irritable bowel Syndrome. Data about effects on acute pain are spare.

The study investigates the effect of an open-label Placebo (substance without a medical active component) application on acute pain, evoked via a artificial pain model in healthy male volunteers. 32 healthy male volunteers are recruited.


Eligibility criteria: Inclusion Criteria:

* Healthy male volunteers (American Society of Anaesthesiologist's Class I or II)
* Body mass index between 18 and 25kg/m2
* Able to understand the study and the NRS scale
* Able to give informed consent

Exclusion Criteria:

* Recreational drug abuse
* Regularly taking medication potentially interfere with pain sensation (analgesics, antihistamines and calcium and potassium channel blockers)
* Neuropathy
* Chronic pain
* Neuromuscular or psychiatric disease
* Known or suspected kidney or liver disease

Primary outcomes:
measure: Pain response measured by the Area under the Pain Curve (AUPC)
timeFrame: 30 minutes after baseline until 100 minutes after baseline
Secondary outcomes:
measure: Differences in pain response measured by the AUPC due to education
timeFrame: 30 minutes after baseline until 100 minutes after baseline
measure: hyperalgesia
timeFrame: 100min
measure: Saliva cortisol concentration in μg/dL
timeFrame: baseline until 100 min after baseline
measure: allodynia
timeFrame: 100minutes
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: University Hospital Basel
state: Basel Stadt
Study officials:
affiliation: Dep. Anesthesiology University Hospital Basel
name: Wilhelm Ruppen, PD
role: STUDY_DIRECTOR
References: